Daily Roundup | BioNTech's Cancer Trial Setback & Roche's Fat-Cell Bet

<p>October 14, 2026 edition, released October 15, 2026. BioNTech&#39;s BNT113 missed progression-free survival in its pivotal head and neck cancer trial, leaving overall survival as the remaining path to a positive result. Roche licensed Rona Therapeutics&#39; undisclosed ALK7-targeting RNAi obesity candidate—a fat-cell approach with most potential deal value contingent on milestones. Johnson &amp; Johnson raised full-year guidance as newer medicines offset Stelara erosion; the roundup also covers FDA review of FYB206, a proposed Keytruda (pembrolizumab) biosimilar, Syndax ending axatilimab in IPF, 84-week Pasatru (garetosmab) data in FOP, and Tremfya (guselkumab) analyses in Crohn&#39;s perianal fistulas.</p><p><br></p><p>Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.</p>